跳至主要内容
临床试验/EUCTR2004-003807-19-ES
EUCTR2004-003807-19-ES进行中(未招募)1 期

A Study to Evaluate the Efficacy and Safety of Ezetimibe/Simvastatin and Fenofibrate Coadministration in Patients With Mixed Hyperlipidemia - Ezetimibe/Simvastatin and Fenofibrate Coadministration Study

Merck & Co Inc.0 个研究点目标入组 600 人开始时间: 2006年1月23日最近更新:
适应症
相关药物

试验速览

阶段
1 期
状态
进行中(未招募)
入组人数
600

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • a.Patient has an LDL-C 130 through 220 mg/dL (3.37 through 5.70 mmol/L) for non-diabetics; LDL-C 100 through 180 mg/dL (2.59 through 4.66 mmol/L) for diabetics, at Visit 2.
  • b.Patient has triglycerides 150 through 500 mg/dL (1.71 through 5.70 mmol/L). [per central laboratory reference ranges] at Visit 2.
  • c.Patient has creatine phosphokinase (CPK) =2 x upper limit of normal (ULN) [per central laboratory reference ranges] at Visit 2.
  • d.Patient has alanine aminotransferase (ALT), and aspartate aminotransferase (AST) =1.5 x upper limit of normal (ULN) [per central laboratory reference ranges] at Visit 2.
  • Are the trial subjects under 18?
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range

排除标准

  • a.You are less than 18 years of age or greater than 79 years of age.
  • b.You are pregnant, breastfeeding, or planning to become pregnant during this study.
  • c.You are a woman able to become pregnant and are not willing to use an acceptable method of birth control. You must be willing to use this birth control starting at Visit 1 and continuing 14 days past the last study dose. The study doctor or staff will discuss which methods of birth control are acceptable for this study.
  • d.You are a woman and have taken cyclical hormone birth control or hormone replacement within 8 weeks of Visit 3.
  • e.You have chronic heart failure, uncontrolled irregular heart beats or a history of heart disease. The study doctor or staff will discuss this with you.
  • f.You have diabetes and are taking lipid lowering medication called statins.
  • g.You have a history of cholelithiasis (gallbladder problems) and you have not had your gallbladder removed.
  • h.You have an active liver disease.
  • i.You are HIV positive.
  • j.You have a history of cancer with in the past 5 years (except for skin cancer that has been successfully treated).
  • k.You have taken any investigational drug within 30 days of visit 1.
  • l.You have a history of drug or alcohol abuse with in the past 5 years
  • m.You are not willing to stop drinking large amounts of grapefruit juice (more than a quart) a day.
  • n.You have a know allergy or history of side effects to medicines similar to the drugs used in this study.

研究者

相似试验

进行中(未招募)
不适用
A Study to Evaluate the Efficacy and Safety of Ezetimibe/Simvastatin and Fenofibrate Coadministration in Patients With Mixed Hyperlipidemia - Ezetimibe/Simvastatin and Fenofibrate Coadministration StudyMixed hyperlipidemiaMedDRA version: 7.0Level: LLTClassification code 10027762
EUCTR2004-003807-19-ATMerck, Sharp & Dohme600
进行中(未招募)
1 期
A Study to Evaluate the Efficacy and Safety of Ezetimibe/Simvastatin and Fenofibrate Coadministration in Patients With Mixed Hyperlipidemia - Ezetimibe/Simvastatin and Fenofibrate Coadministration StudyMedDRA version: 7.0 Level: LLT Classification code 10027762Mixed hyperlipidemia
EUCTR2004-003807-19-GBMerck Sharp & Dohme Ltd600
进行中(未招募)
不适用
A Study to Evaluate the Efficacy and Safety of Ezetimibe/Simvastatin and Fenofibrate Coadministration in Patients With Mixed Hyperlipidemia - Ezetimibe/Simvastatin and Fenofibrate Coadministration StudyMedDRA version: 7.0Level: LLTClassification code 10027762Mixed hyperlipidemia
EUCTR2004-003807-19-HUMerck & Co., Inc.600
已完成
不适用
The study for beneficial efficacy and safety of ezetimibe in patients with hyper LDL-cholesterolemia associated with diabetes mellitus (DM) including glucose intolerance and non-alcoholic fatty liver disease (NAFLD)non-alcoholic fatty liver disease, diabetes mellitus, hyper LDL-cholesterolemia
JPRN-UMIN000004462Geriatric Medicine, Osaka University Graduate School of Medicine20
尚未招募
2 期
Exploratory survey of the safety and efficacy of endoscopic radiofrequency ablation for malignant biliary strictureMalignant biliary stricture
JPRN-UMIN000031601Graduate School of Medicine, Chiba University10